GuidelineZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2025
[Chinese guideline on the diagnosis and treatment of adult primary immune thrombocytopenia (2025)].
Guideline in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Synopsis of the 2025 guideline for the diagnosis and management of adult primary immune thrombocytopenia.Chinese medical journal · 2026Article
- Cost-effectiveness analysis of eltrombopag, hetrombopag and romiplostim for second-line treatment of primary immune thrombocytopenia in China.Frontiers in medicine · 2026Article
- Cost-effectiveness of hetrombopag, eltrombopag, and avatrombopag for chronic immune thrombocytopenia in China: a cost-utility analysis.Frontiers in public health · 2026Article
- Case report: A case of ITP-like thrombocytopenia induced by denosumab.Frontiers in pharmacology · 2026Article
- Glucocorticoids as adjunctive therapy for severe myelosuppression induced by combined immune checkpoint inhibitor and chemotherapy: a case report and literature review.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary immune thrombocytopenia (ITP) is an acquired autoimmune disease characterized by impaired immune tolerance, leading to increased platelet destruction and decreased platelet production. In recent years, with population structure changes and disease management improvements in China, adult ITP exhibits a trend toward older age at presentation and increased incidence. Further, a proportion of patients are at risk of both bleeding and thrombosis. Based on its 2020 edition, this guideline integrates evidence-based medical evidence from domestic and international studies, updates the application of selected laboratory and auxiliary tests in diagnostic evaluation, refines strategies for emergency management and initial therapy, and systematically incorporates new treatment options, including thrombopoietin receptor agonists and small molecule kinase inhibitors. Moreover, it broadens combination regimens for subsequent treatment and places greater emphasis on balancing thrombotic risk and health-related quality of life in long-term management, thereby providing a reference for standardized and individualized care of adult ITP in China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.